BioSpace News Archive

Jersey Community Health (JCH), a 15-clinic hospital network in Jerseyville, IL, has increased revenue and cut countless hours of electronic medical record (EMR) charting per week that providers had been doing after hours, by utilizing real-time remote medical scribes provided by ScribeEMR.

According to Vision Research Reports, the Synthetic Biology market size is expected to surpass around US$ 40.97 billion by 2030 from valued at US$ 10.88 billion in 2020 and growing at a CAGR of 21.8% from 2021 to 2030.

3Spine, Inc., a U.S. medical device company developing total joint replacement for the lumbar spine, announced the appointment of Pierce Nunley, MD, to the company’s Medical Advisory Board.

MaaT Pharma (EURONEXT: MAAT – the “Company”), today announced completion of its Phase 1b CIMON trial evaluating the safety and tolerability of MaaT033, the Company’s high-richness, high-diversity MET for oral administration, in patients with acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (HRMS) having received intensive chemotherapy.

Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced the acceptance of seven key oncology research abstracts authored in collaboration with Illumina at the American Society of Clinical Oncology (ASCO) annual meeting taking place June 3 – June 7 in Chicago.

Cytokinetics, Incorporated announced that Robert I. Blum, President and Chief Executive Officer, is scheduled to participate in the following investor conferences.

4D Molecular Therapeutics, Inc. (Nasdaq: FDMT), a clinical-stage biotherapeutics company harnessing the power of directed evolution for targeted genetic medicines, announced that management will participate in the following upcoming investor conferences.

AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibodies focused on emerging immune control mechanisms applicable to inflammation and immuno-oncology indications, today announced that Dan Faga, chief executive officer, and Paul Lizzul, chief medical officer of AnaptysBio, will represent the company in a fireside chat at the Jefferies Healthcare Conference.

Cognition Therapeutics, Inc. (Nasdaq: CGTX), announced plans to hold a virtual KOL symposium on June 9, 2022, from 10:00 - 11:30 a.m. ET to discuss dry age-related macular degeneration (dry AMD). Cognition plans to initiate a Phase 2 clinical study with CT1812, its lead sigma-2 (σ-2) receptor modulator, in patients with dry AMD in the second half of 2022.

Ginkgo Bioworks, the leading horizontal platform for cell programming, announced that management is scheduled to participate in William Blair’s 42nd Annual Growth Stock Conference, on June 9, 2022, at 11:20 a.m. CT.